BIOCEPT INC
Healthcare · Services-Medical Laboratories · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | |
|---|---|---|---|---|---|---|
| Revenue | $25.9M | $61.2M | $27.5M | $5.5M | $806,943 | $1.7M |
| Operating income | −$32.0M | −$2.4M | −$15.5M | −$23.1M | −$6.3M | −$4.4M |
| Net income | −$32.1M | −$2.8M | −$17.8M | −$25.1M | −$6.4M | −$4.4M |
| Total assets | $30.9M | $60.4M | $47.5M | $17.7M | $14.7M | $17.9M |
| Total liabilities | $22.0M | $22.9M | $23.8M | $6.5M | $5.7M | $6.1M |
| Equity | $8.9M | $37.5M | $23.7M | $11.2M | $3.0M | $1.3M |
| EPS (diluted) | $-1.89 | $-0.19 | $-1.74 | $-12.23 | $-3.33 | $-6.27 |
| Shares out. | 16.9M | 13.4M | 108.7M | 18.8M | 68.0M | 22.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- −123.7%
- Net margin
- −124.1%
- Return on equity
- −362.2%
- Return on assets
- −103.9%
- Return on capital (ROCE)
- −126.1%
- Liabilities / assets
- 71.3%
- Debt / equity
- 2.48×
- Book value / share
- $0.53
- Revenue growth (YoY)
- −57.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- -35.75distress
- Accruals / assets
- −60.9%clean
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 5 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Apr 3, 2023
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2022
- NT 10-Qmissed a reporting deadline ↗Aug 16, 2022
- NT 10-Qmissed a reporting deadline ↗May 16, 2022
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2022
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Material events
SEC Form 8-K · most recent- Delisting / listing-standard noticeOct 20, 2023
- Bankruptcy or receivership · Director / officer changeOct 16, 2023
- Results of operationsAug 22, 2023
- Director / officer changeJun 21, 2023
- Modified shareholder rightsMay 16, 2023
- Results of operations · Delisting / listing-standard notice · Shareholder voteMay 15, 2023
- Results of operationsApr 17, 2023
- Prior financials not reliable (restatement)Apr 17, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 25-NSENov 20, 2023
- 8-KFORM 8-KOct 20, 2023
- 8-KFORM 8-KOct 16, 2023
- 8-KAug 22, 2023
- 10-QAug 14, 2023
- 8-KJun 21, 2023
- 3FORM 3 SUBMISSIONJun 20, 2023
- SC 13GJun 2, 2023
- 424B4May 25, 2023
- EFFECTMay 24, 2023
- CORRESPMay 23, 2023
- CORRESPMay 23, 2023
- S-1/AMay 23, 2023
- CORRESPMay 19, 2023
- CORRESPMay 19, 2023
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.